The FDA has approved lumateperone (Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication.

STANDARD TREATMENT — Antipsychotic drugs are more effective in treating the positive symptoms of schizophrenia (agitation, hallucinations, delusions) than the negative symptoms (apathy, social withdrawal, blunted affect).1 Second-generation antipsychotic drugs are generally used for initial treatment of schizophrenia, even though controlled trials have generally failed to...  Continue reading

A transdermal formulation of the second-generation (atypical) antipsychotic asenapine (Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the first antipsychotic to become available in a transdermal formulation in the US. A twice-daily sublingual tablet formulation of asenapine (Saphris) has been available since ... Continue reading